Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Zezhou Wang"'
A Phase I Study of the Metal Ionophore Clioquinol in Patients With Advanced Hematologic Malignancies
Autor:
Jian Chen, Andre C. Schuh, Christine I. Chen, Zezhou Wang, Mark D. Minden, Aaron D. Schimmer, Yulia Jitkova, Sharon Keays, Tristan Booth, Suzanne Ackloo, Joseph Brandwein, Karen W.L. Yee, Vikas Gupta, Marcela Gronda
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 12:330-336
Clioquinol is a small-molecule metal ionophore that inhibits the proteasome through a metal-dependent mechanism. Here, we report a phase I study of clioquinol in patients with refractory hematologic malignancies. Neuropathy and abdominal pain were do
Autor:
Malik Slassi, Jaehyun Choi, Aaron D. Schimmer, Zezhou Wang, Robert A. Uger, Chunlei Wang, Penka S. Petrova
Publikováno v:
Blood. 128:4719-4719
Small molecule inhibitors of the bromodomain and extraterminal domain (BET) proteins are being actively tested in clinical trials for many cancers, but patient selection strategies remain poorly defined. We have previously demonstrated TTI-281 is an
Autor:
Zezhou Wang, Penka S. Petrova, Jaehyun Choi, Peter Dove, Malik Slassi, Aaron D. Schimmer, Chunlei Wang, Robert A. Uger
Publikováno v:
Blood. 128:2095-2095
Although recent advances in the development of multiple myeloma (MM) therapies such as proteasome inhibitors and immunomodulatory agents have improved patient outcomes, MM remains incurable. Additional therapeutic agents with high efficacy, low toxic
Autor:
Neil MacLean, Wissam Hadri, David O'Neill, Rose Hurren, Peter Dove, Aisha Shamas-Din, Marcela Gronda, Malik Slassi, Clarissa Skorupski, Ahmed Aman, Janessa Li, Zezhou Wang, Rima Al-awar, Aaron D. Schimmer, Feng Bo, Mark D. Minden, Xiaoming Wang
Publikováno v:
Blood. 126:1364-1364
Recent studies have demonstrated the therapeutic potential of targeting BRD2, BRD3 and BRD4 in hematological malignancies including AML. Here, we report a novel orally bioavailable BRD inhibitor, FV-281, that displays preclinical efficacy in AML in v
Autor:
Zezhou Wang, Peter Dove, Xiaoming Wang, Carolyn A. Goard, Zhihua Li, Alex Nachman, Yoonsun Jenny Oh, Rose Hurren, Amy Ruschak, Shane Climie, David O'Neill, Barry Press, Carly Griffin, Elijus Undzys, Ahmed Aman, Rima Al-awar, Lewis Kay, Suzanne Trudel, Malik Slassi, Aaron Schimmer
Publikováno v:
Blood. 122:1988-1988
Proteasome inhibitors (PIs), such as bortezomib and carfilzomib, are often associated with serious toxicities, poor pharmacokinetics (PK), and the inconvenience of intravenous administration. Therefore, there is a need for safer and more effective or
Autor:
Marcela Gronda, Elisa Leung, Etienne Coyaud, Brian Raught, Aaron D. Schimmer, Neil MacLean, Alicia Cole, Fengshu Lin, Rachel Mattson, Walid A. Houry, Kevin R. Coombes, Rose Hurren, Zezhou Wang, Nianxiang Zhang, Mark D. Minden, Steven M. Kornblau, Yihua Qiu, Zenyaho Hao
Publikováno v:
Blood. 122:3937-3937
Caseinolytic protease (ClpP) is a mitochondrial enzyme complex with structural similarity to the cytoplasmic proteasome, but little is known about its function in the mitochondria. We identified ClpP as a potential therapeutic target for acute myeloi
Autor:
Elisa Leung, Neil MacLean, Marcela Gronda, Methvin Isaac, Mohan Babu, Mahadeo A. Sukhai, Walid A. Houry, Aaron D. Schimmer, Zezhou Wang, Fengshu Lin, Rose Hurren, Rachel Mattson, Alicia Cole
Publikováno v:
Blood. 120:3603-3603
Abstract 3603 The mammalian mitochondrial caseinolytic protease (mClpP) is a nuclear-encoded enzyme complex responsible for degrading excess proteins in the mitochondria. It is functionally similar to the proteasome complex in the cytoplasm and struc
Autor:
Jeff Wrana, Marko Skrtic, Bozhena Livak, Neil MacLean, R. Keith Humphries, Angela C. Rutledge, Alessandro Datti, Jessie M. Cameron, Yulia Jitkova, Rose Hurren, Guri Giaever, John E. Dick, Justyna Bartoszko, Jean C.Y. Wang, Shrivani Sriskanthadevan, Xiaoming Wang, Troy Ketela, Marcela Gronda, Courteney Lai, Paul A. Spagnuolo, Jason Moffat, Corey Nislow, Zezhou Wang, Connie J. Eaves, Mark D. Minden, Aaron D. Schimmer, Yanina Eberhard, Brian H. Robinson, Marinella Gebbia
Publikováno v:
Blood. 118:233-233
Abstract 233 To identify novel therapeutic strategies that can eliminate AML and AML stem cells, we screened a library of on and off-patent drugs for candidates that could reduce the viability of engineered human AML cell lines that display the stem